Section Review: Oncologic, Endocrine & Metabolic: Treatments, topics, and trends in ovarian cancer

References

• LA VECCHIA C, LEVI F, LUCCHINI F, NEGRI E, FRANCESCHIS: Descriptive epidemiology of ovarian cancer in Europe. Gynecol. Oncol. (1992) 46(2):208–215.
   PubMed Web of Science ®Google Scholar
• BOYLE P, LA 'VECCHIA C, MAISONNEUVE P. ZHENG T,MACFARLANE GJ: Cancer epidemiology and prevention. In: Oxford Textbook of Oncology. Peckham M, Pinedo HM, Veronesi U (Eds.). Oxford University Press, Oxford (1995):199–276.
   Google Scholar
• SEROV SF, SCULLY RE, SOBIN LH: International histologi-cal classification of tumours, No. 9. In: Histological Typing of Ovarian Tumours. World Health Organization, Geneva (1973).
   Google Scholar
• INTERNATIONAL FEDERATION OF GYNECOLOGY ANDOBSTETRICS: Annual report on the results of treatment In gynecologic cancer. Int. J. Gynecol. Obstet. (1989) 28:189–190.
   Google Scholar
• GREFFTTH CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Int. Monogr. (1975) 42:101.
   PubMedGoogle Scholar
• NEIJT JP, TEN BOKKEL HUININK W, VAN DER BURG MEL, OOSTEROM AT, VRIESENDORP R, KOOYMAN CD, VAN LINDERT ACM, HAMERLYNCK JVTH, VAN LENT M, VAN HOUWELINGEN JC, PINEDO HM: Randomised trial com-paring two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma. The Lancet (1984) 1i:594–600.
   Google Scholar
• NEIJT JP, TEN BOKKEL HUININK W, VAN DER BURG M,VAN OOSTEROM A, WILLEMSE PHB, HEINTZ APM, VAN LENT M, TRIMBOS JB, BOUMA J, VERMORKEN J, VAN HOUWELINGEN J: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs. CP) in advanced ovarian carcinoma. J. Clin. Oncol. (1987) 5:11574168.
   Google Scholar
• OMURA GA, BUNDY BN, BEREK JS, CURRY S, DELGADOG, MORTEL R: A randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J. Clin. Oncol. (1989) 7:457–465.
   PubMed Web of Science ®Google Scholar
• VERMORKEN JB, TEN BOKKEL HUININK WW, EISEN- HAUER EA, FAVALLI G, BELPOMME D, CONTE PF, KAYE SB: Carboplatin versus cisplatin. Ann. Oncol. (1993) 4\(Suppl. 4):41–48.
   Google Scholar
• A well written article discussing studies that compared cisplatin and carboplatin.
   Google Scholar
• MCGUIRE WP: Primary treatment of epithelial malig-nancies. Cancer (1993) 71(4 Suppl.):1541–1550.
   Google Scholar
• TRIMBLE EL, ADAMS JD, VENA D: Parlif2xel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to the National Cancer Institute Treatment Referral Center, 9103. J. Clin. Oncol. (1993) 11:2405–2410.
   PubMed Web of Science ®Google Scholar
• The largest Phase II study with paclitaxel in platinum refractory disease.
   Google Scholar
• MCGUIRE WP: Paclitaxel in the treatment of ovarian cancer. In: Educational Book. American Society of ClinicalOncology, 30th Annual Meeting. Dallas, Texas (1994):204–213.
   Google Scholar
• An extensive review and update of Phase I, II, and III trials of paclitaxel in ovarian cancer.
   Google Scholar
• NEIJT JP: Ovarian can: rethinking prognostic factorsand chemotherapy. Educational Book. American Society of Clinical Oncology, 30th Annual Meeting. Dallas, Texas (1994):214–220.
   Google Scholar
• Ovarian cancer: screening, treatment, and follow up. NIH Consensus Statement (April 5–7, 1994) 12(3):1–30.Management guidelines for all types and stages of ovarian cancer.
   Google Scholar
• Advanced epithelial ovarian cancer: 1993 consensus statements. Ann. Oncol. (1993) 4\(Suppl. 4):83–89.European guidelines for management and research of epithelial ovarian cancer.
   Google Scholar
• LIU PY, ALBERTS DS, FEDERICO M, HANNIGEN EV, GARCIAML, ROTHENBERG ML, DORR RT: CA-125 concentration 8 weeks after treatment initiation independently pre-dicts survival in patients with advanced epithelial ovar-ian cancer: a Southwest Oncology Group (SWOG) study. Proc. ASCO (1995) 14:266.
   Google Scholar
• GERSHENSON DM, MITCHELL MF, ATKINSON N, SILVA EG,KAVANAGH JJ, MORRIS M, BURKE TW, WARNER D, WHAR-TON JT: The effect of prolonged cisplatin-based chemo-therapy on progression-free survival in patients with optimal epithelial ovarian cancer: 'maintenance' ther-apy reconsidered. Gynecol. Oncol. (1992) 47(1):7–13.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SDSO: Chemotherapy of ovarian cancer: islonger better? [Editorial]. Gynecol. Oncol. (1992)47(1):5–6.
   PubMedGoogle Scholar
• BERTELSEN KJAKOBSEN A, STROYER J, NIELSEN K, SAND-BERG E, ANDERSEN JE, AHRONS S, NYLAND M, HJORTKJAER-PEDERSEN P, LARSEN G: A prospective ran-domized comparison of 6 and 12 cycles of cyclophos-phamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol. Oncol. (1993) 49(1):30–36.
   PubMed Web of Science ®Google Scholar
• VAN DER ZEE AG, DUX JM, AALDERS JG, BOONTJE AH,TEN HOOR KA, DE BRUIJN HW: The effect of abdominal surgery on the serum concentration of the tumour-as-sociated antigen CA125. Br. J. Obstet. Gynaecol. (1990) 97:935–938.
   Google Scholar
• RUSTIN JS, NELSTROP A E, MCCLEAN P, BRADY MF, MCGUIRE WE, HOSKINS WJ, MITCHELL H, LAMBERT I111: Defining response of ovarian carcinoma to initial che-motherapy according to serum CA125. Personal commu-nication.
   Google Scholar
• RUSTIN GJS, CRAWFORD M, LAMBERT J, LEDERMANN J,COLEMAN R, MEELY K: Trial of oral hexalen for relapsed ovarian carcinoma: comparison of CA125 and EORTC response definitions. Proceedings ASCO (1995) 14:269.
   Google Scholar
• VAN DER BURG ME; LAMMES FB; VERWEIJ J: The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann. Oncol. (1990) 1(4):301–302. Complete review about the value of CA125 to detect relapse.
   Google Scholar
• NEIJT JP, TEN BOKKEL HUININK WW, VD BURG MEL, V. OOSTEROM AT, WILLEMSE PHB, VERMORKEN JB, VAN LINDERT ACM, HEINTZ APM, AARTSEN E, VAN LENT M, TRIMBOS JB, DE MEIJER AJ: Long-term survival in ovarian cancer. Matured data from The Netherlands Joint Study Group for Ovarian Cancer. Eur.J. Cancer (1991) 27:1367–1372.
   PubMedGoogle Scholar
• This update of Dutch trials provides survival rates for all prognostic important subgroups.
   Google Scholar
• DE LAURENTIIS M., RAVDIN PM: A technique for using neural network analysis to perform survival analysis of censored data. Cancer Letters (1994) 77:127–138.
   PubMed Web of Science ®Google Scholar
• NEIJT JP, VAN DER BURG MEL, TEN BOKKEL HUININK WW, PECOFtELLI S, CURRAN DB, HOCTIN BOES G,THEEU-WEN MMHJ, KAPPEN HJ: Neural nets and prognostic factors in ovarian cancer. Proc. ASCO (1995) 14:267.
   Google Scholar
• OZOLS F, THIGPEN JT, DAUPLAT J, COLOMBO N, PICCART MJ, BERTELSEN K, LEVIN L, LUND B: Dose intensity. Ann. Oncol. (1993) 4\(Suppl. 4):49–56.
   Google Scholar
• MURPHY D, CRO'OC/THER D, RENNISON J, PRENDIVILLE J, RANSON M, LIND M, PATEL U, DOUGAL M, BUCKLEY CH, TINDALL VR: A randomised dose-intensity study in ovar-ian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemother-apy given for twelve cycles. Ann. Oncol. (1993) 4:377–384.
   PubMedGoogle Scholar
• HONG KONG OVARIAN CARCINOMA STUDY GROUP: Arandomized study of high-dose versus low-dose cisplat-inum combined with cyclophosphamide in the treat-ment of advanced ovarian cancer. Chemotherapy (1989) 35:221–227.
   PubMed Web of Science ®Google Scholar
• KAYE SB, LEWIS CR, PAUL J, DUNCAN ID, GORDON HK,KITCHENER HC, CRUICKSHANK DJ; ATKINSON RJ; SOUKOP M; RANKIN EM: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovar-ian cancer. The Lancet (1992) 340:329–333.
   PubMed Web of Science ®Google Scholar
• KAYE SB: Ovarian cancer from the laboratory to the clinic - challenges for the future. Eur. J. Cancer (1995) 31A\(Suppl. 5):574.
   Google Scholar
• MCGUIRE WP, HOSKINS WJ, BRADY MF, HOMESLEY CLARKE-PEARSON DL: A Phase M trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc. ASCO (1992) 11:226.
   Google Scholar
• SHPALL EJ, CAGNONI PJ, BEARMAN SI, PURDY MH, JONESRB: High-dose chemotherapy with autologous he-matopoietic cell support (AHCS) for the treatment of epithelial ovarian cancer. ASCO Educational Book (1995):360–364.
   Google Scholar
• DE VRIES EG, HAMILTON TC, LIND M, DAUPLAT J, NEIJT JP, OZOLS RF: Advanced ovarian cancer. Drug resis-tance, supportive care and dose intensity. Ann. Oncol. (1993) 4\(Suppl. 4):S57–62.
   Google Scholar
• MARKMAN M, REICHMAN B, HAKES T, CURTIN J, JONES W, LEWIS JL, BARAKAT R, RUBIN S, MYCHALC ZAK B SAIGO P, ALMADRONES L, HOSKINS W: Intraperitoneal chemo-therapy in the management of ovarian cancer. Cancer (1993) 71(4 Suppl.):1565–1570,
   Google Scholar
• ALBERTS PY, LIU PY, HANNIGAN EV, ET AL.: Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intrave-nous (W) cyclophosphamide (CPA) vs. IV CDDP/IV CPA In patients (pts) with optimal disease stage HI ovarian cancer: a SW0G-G0G-ECOG intergroup study (lilt 0051). Proc. ASCO (1995) 14:273.
   Google Scholar
• BEREK JS: Interval debulking of ovarian cancer - an interim measure. New Engl. J. Med. (1995) 332:675-677. Review of surgery for ovarian cancer with emphasis on intervention (interval) debulking.
   Google Scholar
• VAN DER BURG, VAN LENT M, BUYSE M, KOBIERSICA A; COLOMBO N, FAVALLI G, LACAVE AJ, NARDI M, RENARD J, PECORELLI S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. New Engl. J. Med. (1995) 332:629–634.
   PubMed Web of Science ®Google Scholar
• NEIJT JP. Interval cytoreduction in ovarian cancer. New Engl. J. Med. (1995) 333:254–255.
   PubMedGoogle Scholar
• GIETEMA JA, WIILFMSE PHB,VAN DER GRAAF wrA, ET AL.: Lobaplatin, a novel platinum analogue, Phase 11 study in patients with relapsed ovarian cancer. Proc. ASCO (1995) 14:274.
   Google Scholar
• HURRIS H, IRVIN R, KUHN J, KALTER S, SMITH L, SHAFFER D, FIELDS S, WEISS G, ECKARDT J, RODRIGUEZ G: Phase I clinical trial of Taxotore administered as either a two hour or a six hour intravenous infusion. j Clin. Oncol. (1993) 11:950–958.
   PubMed Web of Science ®Google Scholar
• PICCART MJ, GORE M, TEN BOKKEL HUININK W, VAN OOSTEROM A, VERWEIJ J, WANDERS J, FRANKLIN H, BAYSSAS M, KAYE S: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. JNCI (1995) 87(9):676–681.
   PubMed Web of Science ®Google Scholar
• LUND B, HANSEN OF, THEILADE K, HANSEN M, NEIJT JP: Phase II study of gemcitabine (2',2'-difluorodeoxycytid-ine) in previously treated ovarian cancer patients. JNCI (1994) 86(20):1530–1533.
   PubMed Web of Science ®Google Scholar
• BURRIS HA, ROTHENBERG ML, ICUHN JG, VON HOFF DD: Clinical trials with the topoisomerase I inhibitors. Sernin. Oncol. (1992) 19(6):663–669.
   PubMed Web of Science ®Google Scholar
• KUDELKA A, EDWARDS C, FREEDMAN R, WALLIN B, HORD M, HOWELL E, HARPER K, RABER M, ICAVANAGH J: A Phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma. ECCO- 7. The 7th European Conference on Clinical Oncology and Cancer Nursing. Eur J Cancer (1993) 29A(6):132.
   Google Scholar
• MCGUIRE WP, HOSKINS WJ, BRADY MF, KUCERA PR, PARTRIDGE EE, LOOK KY, DAVIDSON M: Taxol and cisplatin (tp) improves outcome in advanced ovarian cancer (aoc) as compared to cytoxan and cisplatin (cp). Proc. ASCO (1995) 14:275.
   Google Scholar
• EISENHAUER EA, TEN BOKKEL HUININK WW, SWENER- TON ICD, GIANNI L, MYLES J, VAN DER BURG ME, KERR I,VERMORICEN JB, BUSER K, COLOMBO N: European-Cana-dian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J. Clin. Oncol. (1994) 12:2654–2666.
   PubMed Web of Science ®Google Scholar
• This study not only shows that a high dose, and short infusion of paclitaxel is feasible but also provides a good analysis of prognostic factors predicting response and progression-free survival to treat-ment of relapse.
   Google Scholar
• CONNELLY E, MARKMAN M, WEBSTER K, KENNEDY A, KULP B, PETERSON G, BELINSON J: Three hour infusional taxol with cisplatin in patients with gynecological can-cers. Proc. ASCO (1995) 14:277.
   Google Scholar
• ROWINSICY EK, CHALTDHRY V, FORASTIERE AA, SARTO-RIUS SE, ETTINGER DS, GROCHOW LB, LUBEJKO BG, CORNBLATH DR, DONEHOWER RC: Phase I and pharma-cologic study of paclitaxel and cisplatin with granulo-cyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. (1993) 11:2010–2020.
   PubMed Web of Science ®Google Scholar
• TEN BOKKEL HUININK WW, VEENHOF CHN, HUIZING M,ET AL.: Carboplatin and paclitaxel (Taxol) in patients with advanced ovarian cancer, a dose finding study. Ann. Oncol. (1994) 5\(Suppl. 8):99.
   Google Scholar
• GIACCONE G, HUIZING M, TEN BOKKEL HUININK W,KOOLEN M, POSTMUS P, VAN KRALINGEN K, VAN ZAND-WIJK N, VERMORKEN J, BEIJNEN J, DALESIO O: Prelimi-nary results of two dose-finding studies of parlitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort. Semtn. Oncol. (1994) 21(5 Suppl. 8):34–38.
   Google Scholar
• CALVERT AH, NEWELL DR, GUMBRELL LA, ET AL.: Car-lboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. (1989) 17(11):1748–1756.
   Google Scholar
• BOOKMAN MA, MCGLTIRE WP, KILPATRICK, ET AL.: Phase1 gynecologic oncology group (GOG) study of 3-h and 24-h pacittaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (ovca). Proc. ASCO (1995) 14:271.
   Google Scholar
• HOSKINS PJ, O'REILLY SE, SWENERTON KD: The 'failurefree interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovar-ian cancer previously treated with cisplatim relevance to therapy and new drug testing. Int. J. Gynecol. Cancer (1991) 1:205–208.
   Web of Science ®Google Scholar
• MAICAR AP, KRISTENSEN GB, BORMER OF, TROPE CG: Is serum CA 125 at the time of relapse a prognostic Indicator for further survival prognosis in patients with ovarian cancer? Gynecol. Oncol. (1993) 49(1):3–7.
   Google Scholar
• VAN DER BURG ME, LAMMES FB, VERWEIJ J: The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Stag. Gynecol. Ob-stet. (1993) 176(4):310–314.
   PubMed Web of Science ®Google Scholar
• RUSTIN GJ, VAN DER BURG ME, BEREK JS: Advanced ovarian cancer. Tumour markers. Ann. Oncol. (1993) 4\(suppl. 4):S71–77.
   Google Scholar
• MARKMAN M, HAKES T, REICHMAN B, BARAKAT R, CUR-TIN J, JONES W, LEWIS JL JR, RUBIN S, ALMADRONES L, HOSKINS W: Exploring the use of chronic low-dose oral etoposide in ovarian cancer: Is there a role for this 'New Drug' in the management of platinum-refractory dis-ease? Sem. Oncol. (1992) 19(6 Suppl. 14):25–27.
   Google Scholar
• HOSKINS PJ, SWENERTON KD: Oral etoposide is active against platinum-resistant ovarian cancer. J. Ctn. Oncol. (1994) 12:60–63.
   PubMed Web of Science ®Google Scholar
• SEYMOUR MT, MANSI JL, GALLAGHER CJ, GORE ME, HAR-PER PG, EVANS TRJ, EDMONS PM, SLEVIN ML: Protracted oral etoposide in epithelial ovarian cancer: a Phase II study in patients with relapsed or platinum-resistant disease. Br.J. Cancer (1994) 69:191–195.
   PubMed Web of Science ®Google Scholar
• FOSTER BJ, CLAGETT-CARR K, MARSONI S, SIMON R, LEYLAND-JONES B: Role of hexamethylmelamine in the treatment of ovarian cancer, where is the needle in the haystack? Cancer Treat. Rep. (1986) 70:1003–1014.
   Google Scholar
• SCHINK JC, NARRIS LS, GROSEN EA, I3ALLEY HH: Altre-tamine ('llexalen') an effective salvage chemotherapy after paclitaxel ('Taxol') in women with recurrent plati-num resistant ovarian cancer. Proc. ASCO (1995) 14:275.
   Google Scholar
• HAUGE MD, LONG HJ, HARTMANN LC, EDMONSON JH, WEBB MJ, SU J: Phase II trial of intravenous hexamethyl-melamine in patients with advanced ovarian cancer. Invest. New Drugs (1992) 10:299–301.
   PubMed Web of Science ®Google Scholar
• HATCH KD, BEECHAM JB, BLESSING JA, CREASMAN WT: Responsiveness of patients with advanced ovarian car-cinoma to tamoxifen. Cancer(1991) 68(2):269–271.
   PubMed Web of Science ®Google Scholar
• HANSEN HH, EISENHAUER EA, HANSEN M, NEIJT JP, PICCART MJ, SESSA C, THIGPEN Yr: New cytotoxic drugs in ovarian cancer. Ann. Oncol. (1993) (4) 4:63–70.
   Google Scholar